Literature DB >> 26605259

Measles may be a Risk Factor for Malignant Brain Tumors.

Steven Lehrer1, Sheryl Green1, Angela Rendo2, Kenneth E Rosenzweig1.   

Abstract

BACKGROUND: A possible risk factor for brain tumor might be measles, since late neurologic sequelae are part of measles pathology. Subacute sclerosing panencephalitis, a devastating neurologic illness, is prone to develop years after measles infection.
METHODS: Because measles damage to the brain might increase the risk of brain tumor, we examined the relationship of measles incidence in 1960 and brain tumor incidence in 50 US States and the District of Columbia, 2004-2007. Data on number of cases of measles by state in 1960 are from the Morbidity and Mortality Weekly Report. In 1960 measles was a childhood illness. We calculated measles incidence by obtaining the population of each state from the 1960 US Census and then age adjusting our results to the cumulative percent of the state population under age 21, since this would have been the measles-infected group. Data on the percentage white population by state are from the US Census (www.census.gov). Age-adjusted incidence (to the 2000 US standard population) of brain tumors is from the Central Brain Tumor Registry of the United States 2011 report.
RESULTS: There was a significant correlation between 1960 measles incidence and incidence of malignant brain tumors in persons 20 and older in 2004-2007 (r=0.321, p=0.026). Because glioblastoma is more frequent in whites and males, multivariate linear regression was performed with tumor incidence as the dependent variable, measles incidence, percent white population, and sex ratio by state as independent variables. Measles incidence was significantly correlated with malignant brain tumor incidence (β=0.361, p<0.001) and independent of the effect of race (β=0.734, p<0.001) and sex ratio m/f (β=-0.478, p<0.001). There was no correlation of measles incidence with brain tumor incidence in persons younger than 20.
CONCLUSION: Inflammation is a critical component of tumor development. The inflammation of measles-induced subacute sclerosing panencephalitis, even subclinical cases, could well promote tumor formation, since many tumors arise from sites of infection, chronic irritation and inflammation.

Entities:  

Keywords:  Brain tumors; Glioma; Measles; Meningioma

Year:  2015        PMID: 26605259      PMCID: PMC4642282          DOI: 10.14791/btrt.2015.3.2.65

Source DB:  PubMed          Journal:  Brain Tumor Res Treat        ISSN: 2288-2405


INTRODUCTION

Primary brain tumors account for 2% of cancer deaths. Gliomas make up 60% of these tumors and are frequently malignant. Meningioma is a benign tumor that represents 20% of brain neoplasms. Hereditary syndromes are well established risk factors for both glioma and meningioma [1]. Meningioma incidence increases with age. Ionizing radiation and head trauma may be risk factors [2]. Glioblastoma multiforme is the most common and most aggressive type of primary brain tumor, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. Gliomas are more common in whites, and appear to be sporadic, most without any genetic predisposition. Ionizing radiation is a risk factor [1]. No conclusive links have been found between gliomas and smoking, diet, cellular phones, or electromagnetic fields. Recently, evidence for a viral cause for glioblastoma multiforme, human cytomegalovirus (CMV), has been postulated, although the evidence is inconsistent [3456]. A possible risk factor for brain tumor might be measles, since late neurologic sequelae are part of measles pathology. Subacute sclerosing panencephalitis, a devastating neurologic illness, is prone to develop years after measles infection [7]. The measles virus has immunosuppressive properties [8] that could promote the development of tumors. Moreover, Cattaneo et al. [9] have found biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Clusters of mutations favor the propagation of the virus within the brain. Because measles damage to the brain might increase the risk of brain tumor, we examined the relationship of measles incidence in 1960 and brain tumor incidence in 49 US States and the District of Columbia, 2004-2007. Measles was a non-notifiable infectious disease in Kansas, 1960, and so this one state is not included.

MATERIALS AND METHODS

Data on number of cases of measles by state in 1960 are from Table 5 of Morbidity and Mortality Weekly Report [10]. In 1960 measles was a childhood illness. We calculated measles incidence by obtaining the population of each state from the 1960 US Census and then age adjusting our results to the cumulative percent of the state population under age 21, since this would have been the measles-infected group. The 1960 data were chosen because they are the only published data on measles incidence in the US before the advent of measles vaccine. Data on the percentage white population and sex ratio by state are from the US Census (www.census.gov). Age-adjusted incidence (to the 2000 US standard population) of brain tumors 2004-2007 is from Table 10 of the Central Brain Tumor Registry of the United States 2011 report [11]. We chose this set of tumor data because it is the most recent available broken down by age group.

RESULTS

There was a significant correlation between 1960 measles incidence and incidence of malignant brain tumors in persons 20 and older in 2004-2007 (r=0.321, p=0.026) (Fig. 1). Because glioblastoma is more frequent in whites and males, multivariate linear regression was performed with tumor incidence as the dependent variable, measles incidence, percent white population, and sex ratio by state as independent variables. Measles incidence was significantly correlated with malignant brain tumor incidence (β=0.361, p<0.001) and independent of the effect of race (β=0.734, p<0.001) and sex ratio m/f (β=-0.478, p<0.001). There was no correlation of measles incidence with brain tumor incidence in persons younger than 20.
Fig. 1

Age adjusted malignant brain tumor incidence (2004-2007) in 50 US states and the District of Columbia (cases per 100,000) versus 1960 age adjusted measles incidence (cases per 10,000). The correlation is significant (p=0.026).

There was a significant correlation between 1960 measles incidence and incidence of non-malignant brain tumors (r=0.305, p=0.035) in persons 20 and older in 2004-2007. However, in a multivariate analysis, the correlation of measles incidence and non-malignant brain tumor incidence only approached significance (β=0.286, p=0.063) and was unrelated to race (β=0.071, p=0.643) or sex ratio m/f (β=-0.004, p=0.981).

DISCUSSION

There have been attempts to implicate various viruses in the genesis of brain tumors. Polyomaviruses, including the JC virus, the BK virus, and simian virus 40, have been identified in human glioma tissues and have induced brain tumors in animals [12]. A herpes virus, human CMV, is implicated in glioblastoma, and one report found CMV circulating in the peripheral blood of 80% of patients [5]. Although we were unable to replicate this finding [4], a consensus holds that CMV plays a role [13]. Measles virus might also predispose to brain tumors. The inflammation of subacute sclerosing panencephalitis, even subclinical cases, could well promote tumor formation, since many tumors arise from sites of infection, chronic irritation and inflammation [14]. Moreover, inflammation is a critical component of tumor progression. The absence of correlation of measles incidence with brain tumor incidence in persons younger than 20 is expected. These people would not have been included in the 1960 Morbidity and Mortality Weekly Report, and would be, in general, too young to be significantly affected by meningioma or glioma. A weakness in our analysis, presented above, is possible confounding by the ecological fallacy (or ecological inference fallacy), a logical fallacy in the interpretation of statistical data where inferences about the nature of individuals are derived from inference for the group to which those individuals belong [15]. In this case, inferences about individuals are being drawn from the characteristics of US states where they reside, rather than from the individuals themselves. Another problem with our analysis is that populations are mobile and there is no way to factor in such movements over a forty-five year latency period. Finally, an intrinsic difficulty with correlational studies is that two variables may be associated, even if there is no causal link between them, if each is associated with some other variable. It would be desirable to analyze measles incidence data from other decades to see if results are consistent or depend on lag period. However, no other measles incidence data sets are publicly available. Malignant brain tumors are highly heterogeneous and ideally should not be lumped together as one category. Analyses would be best performed separately for tumor types and grades, and also by demographic variables where data are available. However, these parameters are not available tabulated by state, and this type of analysis was not possible with the data at hand. It would be worthwhile to adjust for proportions of each major racial group, rather than only percentage white population. However, US 2010 census data are broken down by proportion of each major racial group overall, but only by non-Hispanic white alone versus minority on a state by state basis. The first live virus measles vaccine (Rubeovax by Merck) was licensed in 1963, and measles was declared to be eliminated in the United States in 2000. But importation of measles cases and limited local transmission continue to occur [7]. Parents who refuse to vaccinate their children because of fears of autism and other chimerical sequelae of vaccination have made the situation worse. And the vaccine is not 100% effective, leading to outbreaks even in highly vaccinated groups, especially if vaccination rates fall below 95% and community immunity drops [16]. Therefore, further study of a possible measles-brain tumor association would be worthwhile.
  13 in total

1.  Consensus on the role of human cytomegalovirus in glioblastoma.

Authors:  Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

Review 2.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

4.  No consistent relationship of glioblastoma incidence and cytomegalovirus seropositivity in whites, blacks, and Hispanics.

Authors:  Steven Lehrer; Sheryl Green; Lakshmi Ramanathan; Kenneth Rosenzweig; Vincent Labombardi
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

5.  CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus.

Authors:  E C Hsu; C Iorio; F Sarangi; A A Khine; C D Richardson
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

6.  Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated.

Authors:  David E Sugerman; Albert E Barskey; Maryann G Delea; Ismael R Ortega-Sanchez; Daoling Bi; Kimberly J Ralston; Paul A Rota; Karen Waters-Montijo; Charles W Lebaron
Journal:  Pediatrics       Date:  2010-03-22       Impact factor: 7.124

Review 7.  Epidemiology of intracranial meningioma.

Authors:  W T Longstreth; L K Dennis; V M McGuire; M T Drangsholt; T D Koepsell
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors.

Authors:  Dana E M Rollison; Kathy J Helzlsouer; Anthony J Alberg; Sandra Hoffman; Jean Hou; Richard Daniel; Keerti V Shah; Eugene O Major
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

10.  Biased hypermutation and other genetic changes in defective measles viruses in human brain infections.

Authors:  R Cattaneo; A Schmid; D Eschle; K Baczko; V ter Meulen; M A Billeter
Journal:  Cell       Date:  1988-10-21       Impact factor: 41.582

View more
  4 in total

1.  Height, waist circumference, body mass index, and body somatotype across the life course and risk of glioma.

Authors:  David J Cote; Mary K Downer; Timothy R Smith; Stephanie A Smith-Warner; Kathleen M Egan; Meir J Stampfer
Journal:  Cancer Causes Control       Date:  2018-06-26       Impact factor: 2.506

Review 2.  Role of Redox Status in Development of Glioblastoma.

Authors:  Aleli Salazar-Ramiro; Daniela Ramírez-Ortega; Verónica Pérez de la Cruz; Norma Y Hérnandez-Pedro; Dinora Fabiola González-Esquivel; Julio Sotelo; Benjamín Pineda
Journal:  Front Immunol       Date:  2016-04-26       Impact factor: 7.561

3.  Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies.

Authors:  Xiao Yu; Nian Rong Sun; Hai Tao Jang; Shi Wen Guo; Min Xue Lian
Journal:  Oncotarget       Date:  2017-09-18

Review 4.  Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma.

Authors:  Michele Persico; Claudia Abbruzzese; Silvia Matteoni; Paola Matarrese; Anna Maria Campana; Veronica Villani; Andrea Pace; Marco G Paggi
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.